Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on January 28, 2013. The report details a specific corporate transaction involving the exchange of securities between the company and one of its stockholders.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure transaction.
Material Changes
On January 28, 2013, the Company entered into a Securities Exchange Agreement with a non-affiliate stockholder. The material terms of this transaction are:
- Shares Issued: 116,894 shares of Common Stock ($0.001 par value).
- Shares Surrendered: 65,013 shares of 6% Exchangeable Convertible Preferred Stock.
- Transaction Type: An exchange of securities initiated by the stockholder, settled on February 1, 2013.
- Regulatory Basis: The issuance relied on the Section 3(a)(9) exemption of the Securities Act of 1933.
- Post-Transaction Status: Following the settlement, 796,139 shares of Preferred Stock remained outstanding.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the description of the exchange transaction. The transaction was determined through arms-length negotiations, and no commission or remuneration was paid by the issuer for soliciting the exchange.
Investor Verification Checklist
- Verify the total outstanding share count of Common Stock following the issuance of 116,894 new shares.
- Confirm the remaining 796,139 shares of 6% Exchangeable Convertible Preferred Stock and their conversion terms.
- Review the specific rights and preferences of the Preferred Stock being exchanged to understand the dilution impact on existing shareholders.
- Check subsequent filings for any additional exchanges or changes to the capital structure.